

## 12-8056: Anti-Human CTLA-4 (Ipilimumab) - HRP

<b>Clonality :</b>	Monoclonal
<b>Clone Name :</b>	MDX-010
<b>Application :</b>	ELISA
<b>Reactivity :</b>	Human
<b>Alternative Name :</b>	CD; GSE; GRD4; ALPS5; CD152; CTLA-4; IDDM12; CELIAC3
<b>Isotype :</b>	Human IgG1k
<b>Immunogen Information :</b>	Human CTLA-4

### Description

Expression Host : HEK-293

This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Ipilimumab. Ipilimumab binds to Human CTLA-4. This product is for research use only.

Cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) is a protein receptor that serves as an immune checkpoint and down-regulates the immune system. CTLA-4 is constitutively expressed in regulatory T cells but is only upregulated in conventional T cells following activation. Many cancers, including Melanoma, are associated with CTLA-4 upregulation because the body's ability to recognize and destroy cancer cells is hampered by an inhibitory mechanism. Ipilimumab targets CTLA-4 and works by turning off this inhibitory mechanism and, thus, enhances the body's own immune response against cancer cells. Emerging research suggests that combined blockade of PD-1 and CTLA-4, with Nivolumab and Ipilimumab respectively, could produce greater antitumor activity than blockade of either pathway alone.<sup>1</sup> This cost-effective, research-grade Anti-Human CTLA-4 (Ipilimumab) utilizes the same variable regions from the therapeutic antibody Ipilimumab making it ideal for research projects.

### Product Info

<b>Amount :</b>	100 µg Concentration : 0.5 mg/ml
<b>Content :</b>	This HRP-conjugated antibody is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4, 1% BSA. (Warning: Use of sodium azide as a preservative will inhibit the enzyme activity of horseradish peroxidase)
<b>Storage condition :</b>	This horseradish peroxidase conjugated monoclonal antibody is stable when stored at 2-8°C. Do not freeze.

### Application Note

The suggested concentration for Ipilimumab biosimilar antibody for staining cells in flow cytometry is  $\leq 1.0$  µg per 10<sup>6</sup> cells in a volume of 100 µl. Titration of the reagent is recommended for optimal performance for each application. ELISA